Literature DB >> 23151134

Dissecting bortezomib: development, application, adverse effects and future direction.

Biyin Cao1, Jie Li, Xinliang Mao.   

Abstract

Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23151134     DOI： 10.2174/13816128113199990338

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN： 1381-6128            Impact factor:   3.116


  13 in total

1.  Functional chromatography reveals three natural products that target the same protein with distinct mechanisms of action.

Authors:  Min Jin Kang; Tongde Wu; E M Kithsiri Wijeratne; Eric C Lau; Damian J Mason; Celestina Mesa; Joseph Tillotson; Donna D Zhang; A A Leslie Gunatilaka; James J La Clair; Eli Chapman
Journal:  Chembiochem       Date:  2014-08-14       Impact factor: 3.164

2.  Structural and Functional Analysis of Ubiquitin-based Inhibitors That Target the Backsides of E2 Enzymes.

Authors:  Pankaj Garg; Derek F Ceccarelli; Alexander F A Keszei; Igor Kurinov; Frank Sicheri; Sachdev S Sidhu
Journal:  J Mol Biol       Date:  2019-10-19       Impact factor: 5.469

3.  Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.

Authors:  Pilar de la Puente; Micah J Luderer; Cinzia Federico; Abbey Jin; Rebecca C Gilson; Christopher Egbulefu; Kinan Alhallak; Shruti Shah; Barbara Muz; Jennifer Sun; Justin King; Daniel Kohnen; Noha Nabil Salama; Samuel Achilefu; Ravi Vij; Abdel Kareem Azab
Journal:  J Control Release       Date:  2017-11-28       Impact factor: 9.776

4.  Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.

Authors:  Mingjun Zhang; Jin He; Zhiqiang Liu; Yong Lu; Yuhuan Zheng; Haiyan Li; Jingda Xu; Huan Liu; Jianfei Qian; Robert Z Orlowski; Larry W Kwak; Qing Yi; Jing Yang
Journal:  Oncotarget       Date:  2015-04-20

5.  Targeting Human β-Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment.

Authors:  Mingjun Zhang; Jin He; Jing Yang
Journal:  Chemotherapy (Los Angel)       Date:  2016-02-20

Review 6.  Trial Watch: Proteasomal inhibitors for anticancer therapy.

Authors:  Florine Obrist; Gwenola Manic; Guido Kroemer; Ilio Vitale; Lorenzo Galluzzi
Journal:  Mol Cell Oncol       Date:  2014-12-01

7.  Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma.

Authors:  Hong-Guang Jin; Guo-Zhen Wu; Guo-Hua Wu; Yong-Ge Bao
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

Review 8.  Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective.

Authors:  Patrizia Russo; Alessandra Del Bufalo; Massimo Fini
Journal:  EXCLI J       Date:  2015-02-10       Impact factor: 4.068

9.  A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo.

Authors:  Juan Tang; Jingyu Zhu; Yang Yu; Zubin Zhang; Guodong Chen; Xiumin Zhou; Chunhua Qiao; Tingjun Hou; Xinliang Mao
Journal:  Oncotarget       Date:  2014-06-15

Review 10.  The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.

Authors:  Giovanni Barillari; Paolo Monini; Cecilia Sgadari; Barbara Ensoli
Journal:  Int J Mol Sci       Date:  2018-05-09       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.